Cumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cumberland Pharmaceuticals (CPIX) Misses Q3 EPS by 10c
November 12, 2019 4:32 PM ESTCumberland Pharmaceuticals (NASDAQ: CPIX) reported Q3 EPS of $0.01, $0.10 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $10.4 million versus the consensus estimate of $12.65 million.
For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.
... More